HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells.

导出 OA

翻译打印收藏纠错

作者： Jung,Yoo ^[1] ; Yu Hyun,Jeon ^[1] ; Dong Hoon,Lee ^[1] ; Go Woon,Kim ^[1] ; Sang Wu,Lee ^[1] ; So Yeon,Kim ^[1] ; Jongsun,Park ^[2] ; So Hee,Kwon ^[3]

作者单位： Department of Pharmacy, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea. ^[1] Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea. ^[2] Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea. ^[3] Department of Integrated OMICS for Biomedical Science, Yonsei University, Seoul 03722, Republic of Korea. ^[4]

关键词 A452 ACY-241 citarinostat combination therapy histone deacetylase 6 ovarian cancer paclitaxel

DOI 10.3892/ol.2021.12462

PMID 33574940

发布时间 2021-02-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交